🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

CTOS President Silvia Stacchiotti is inviting everyone to join the Annual Meeting in Boca Raton and celebrate 30th Anniversary of the Society! Get ready and prepare your abstracts! Especially on the #sarcoma of the year 🌟#chondrosarcoma #CTOS2025 #CTOSTweeTOS

Discussing of barriers and ethical choices in clinical trials and pediatric research. thanks for sharing your insights #jonathantrent and Aditi Dhir! Miami Uni Promo Sylvester Comprehensive Cancer Center gilberto lopes

One of the many things about large scale precision oncology programs: they enable discovery of new entities. EP300::VGLL3 rhabdomyosarcoma: a potential distinct indolent adult rhabdomyosarcoma subtype - ESMO Rare Cancers esmorarecancers.org/article/S3050-… Omico Australia UNSW

Liz Connolly Australia and New Zealand Sarcoma Association Fiona Maclean Professor DM Thomas Tom Wei-Wu Chen Silvia Stacchiotti Inga-Marie Schaefer Jason L. Hornick, M.D., Ph.D. Paolo Dei Tos Tristan Rutland MBBS FRCPA IFCAP Beautiful report! Thanks to the ANZSA friends for this! We hope that our PUSH series on S-RMS will also help shed light on these ultra-rare entities and provide further insights into this potential distinct subtype. Stay tuned!

Abstract submissions are now open for the 2025 ANZSA Annual Scientific Meeting. We’re inviting poster submissions from all areas of sarcoma research! Deadline: Friday 1 August 2025 (midnight AEST) 📎 Follow the submission instructions at: aoa.org.au/events/cem-eve…

So proud, for my first #ASCO25, to present work on pediatric #TGCT on behalf of TGCT Support ☺️ grateful for the opportunity to raise awareness

MANEUVER study results presented at ASCO 2025, Sarcoma Oral Session. Pimicotinib was able to induce 54% RECIST and 61.9% volumetric responses in patients with symptomatic TGCT. Honoured to be part of this study #ASCO2025 #TGCT #sarcoma

PFS benefit with anlotinib+doxo and anlotinib maintenance. Lower than expected ORR in doxo arm and almost impossible to believe equivalence in toxicity between the arms. Same question as doxo+trabectedin: what if sequential single agent were used? #ASCO25

Interesting data with camrelizumab +apatinib in chordoma. Great to see activity in #chordoma #ASCO25

Exciting initial activity of TDXd in DSRCT. #ASCO25

KS is still one of the most common cancers in the world. Phenomenal activity with abemaciclib. #ASCO25

The OG Dr. Wagner ⁦⁦Dana-Farber⁩ with an excellent summary of exciting new #sarcoma data at #ASCO25

⁦Vinod Ravi, MD⁩ with an excellent summary of decades of work looking at neoadjuvant/adjuvant chemo for #sarcoma . Still no consensus.

For the first time, we’ve set benchmark values for surgery in primary retroperitoneal liposarcoma (WDLPS/DDLPS). 15 expert centres. 22 key metrics. A new standard for measuring surgical quality. Presented at #CTOS2024. Great collaborative effort from TARPSWG.

After the inspiring ASCO meeting we are looking forward to meeting all the sarcoma family again at #CTOS2025! Patient advocacy groups are valuable members of our community! ⬇️Check the invitation from Kathrin Schuster from SPAGN and CTOS Outreach Committee

🚨 ASCO #ASCO25 was absolutely incredible! 🧬✨ So many groundbreaking advances in oncology and exciting publications that are going to change patient care. 👉Sharing the key ones below The Lancet The Lancet Oncology Journal of Clinical Oncology JAMA JAMA Oncology Cancer Discovery - Also added the

Tiny world and full circle moment From 🇮🇪 to meeting in 🇫🇷 at the ESMO - Eur. Oncology medical student poster walk at #ESMO2022 to a visit to 🇦🇺 Clara it was great to show you around @PeterMacCC_ & lovely to hear about what you’ve been up too since! #FutureMedOnc #ESMOYOC #mentorship

We’re pleased to announce that Winship Cancer Institute of Emory University in the US, is the second international site to join the ReLaPSe study - a prospective study evaluating standard treatment options for patients who’ve had a recurrence of a resected #retroperitoneal #liposarcoma.